CAS: 633-47-6; Cropropamide

该化合物是一种化学化合物,主要用于管理2型糖尿病,主要用于管理2型糖尿病,主要用作口服低血糖剂,促进胰腺分泌,提高胰岛素的边缘性胰岛素敏感性;propamide的分子结构包括一个具有其类别特征的,有助于其药理活动的磺酰胺组;它通常以平板形式施用,并已知其行动时间相对较长;Cropropamide一般在胃肠道中被吸收,其新陈代谢主要出现在肝脏中;副作用可能包括缺血,胃肠扰动和过敏反应,尽管这些反应并非普遍都经历过;与任何药物一样,对病人的功效和潜在不利影响进行监测至关重要;

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号84803-62-3 N,N-Dimethyl-2-... | CAS号10487-71-5 丁烯酰氯

合成工艺路线路线简述

    📜Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于sodium Amide,Xylene体系中,化学反应生成 克罗丙胺
    参考文献:Ch245911
    标题:Ch245911

    海关参考信息

    专利信息


    专利号:US-2024287041-A1
    优先权日:2021-05-20
    标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
    发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

    专利号:US-9994558-B2
    优先权日:2013-09-20
    标题 :Multicyclic compounds and methods of using same
    发明人:BALOGLU ERKAN; SHACHAM SHARON; SENAPEDIS WILLIAM; MCCAULEY DILARA; LANDESMAN YOSEF; GOLAN GALI; KALID ORI; SHECHTER SHARON
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).

    专利号:WO-2022246227-A1
    优先权日:2021-05-20
    标 题:Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms

    专利号:US-10363247-B2
    优先权日:2015-08-18
    标 题:(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
    发明人:BALOGLU ERKAN; SHACHAM SHARON; SENAPEDIS WILLIAM
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

    专利号:EP-4341253-A1
    优先权日:2021-05-20
    标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms

    专利号:US-7993390-B2
    优先权日:2002-02-08
    标 题:Implantable or insertable medical device resistant to microbial growth and biofilm formation
    发明人:MILLER KATHLEEN M; BUCAY-COUTO WEENNA; LI JIANMIN
    权利人:BOSTON SCIENT SCIMED INC
    摘要:Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and/or a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sams RA, Gerken DF, Ashcraft SM. Pharmacokinetics of intravenous and oral prethcamide in horses. J Pharm Biomed Anal. 1997 Feb;15(5):639-51. doi: 10.1016/s0731-7085(96)01885-7. 606(2):217-22. doi: 10.1016/j.aca.2007.10.053. Epub 2007 Nov 9. 194(2):240-6. doi: 10.1016/j.tvjl.2012.04.007. Epub 2012 May 18. 14(5):455-63. doi: 10.1159/000136628. 12(5):327-9. doi: 10.1016/j.parkreldis.2005.11.007. Epub 2006 Feb 3. 7(4):389-96. doi: 10.1002/bdd.2510070408. 657(1):45-52. doi: 10.1016/j.aca.2009.10.016. Epub 2009 Oct 27. 37(5):653-61.

    合成参考文献


    参考文献:10.1016/j.aca.2009.10.016
    摘要:Lu J, Wang S, Dong Y, Wang X, Yang S, Zhang J, Deng J, Qin Y, Xu Y, Wu M, Ouyang G. Simultaneous analysis of fourteen tertiary amine stimulants in human urine for doping control purposes by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry. Anal Chim Acta. 2010 Jan 04;657(1):45–52. doi: 10.1016/j.aca.2009.10.016.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知